Antipsychotic Class Warning On Cerebrovascular Events Under FDA Review
FDA is considering class labeling for atypical antipsychotics on an increased risk of cerebrovascular events in elderly dementia patients
You may also be interested in...
FDA is asking manufacturers of atypical antipsychotics to add a "black box" warning to labeling on an increased mortality risk associated with the drugs' off-label use to treat dementia-related behavioral disorders
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011